➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Baxter
Express Scripts
AstraZeneca
McKinsey

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for Patent: RE43879


Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE43879 protect, and when does it expire?

Patent RE43879 protects FETZIMA and is included in one NDA.

This patent has forty-six patent family members in twenty-seven countries.

Summary for Patent: RE43879
Title:Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
Abstract: The present invention concerns the use of a mixture of enantiomers enriched in the dextrogyral enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts, for the preparation of a drug intended to prevent or to treat disorders that can be managed by double inhibition of serotonin (5-HT) and norepinephrine (NE) reuptake, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity.
Inventor(s): Deregnaucourt; Jean (Paris, FR), Grosse; Richard (Gidy, FR)
Assignee: Pierre Fabre Medicament (Paris, FR)
Application Number:13/406,415
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE43879
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent RE43879

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-001 Jul 25, 2013 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ⤷  Free Forever Trial
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-002 Jul 25, 2013 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ⤷  Free Forever Trial
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-003 Jul 25, 2013 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ⤷  Free Forever Trial
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-004 Jul 25, 2013 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE43879

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France03 01849Feb 14, 2003

International Family Members for US Patent RE43879

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 401872 ⤷  Free Forever Trial
Austria 501716 ⤷  Free Forever Trial
Australia 2004216452 ⤷  Free Forever Trial
Brazil PI0407256 ⤷  Free Forever Trial
Canada 2514948 ⤷  Free Forever Trial
China 1750817 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Colorcon
Medtronic
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.